Further Evidence of Neuroprotective Effects of Recombinant Human Erythropoietin and Growth Hormone in Hypoxic Brain Injury in Neonatal Mice.
Animals
Animals, Newborn
Brain Injuries
/ drug therapy
Endothelial Cells
/ metabolism
Erythropoietin
/ pharmacology
Growth Hormone
Humans
Hypoxia
/ drug therapy
Mice
Neuroprotective Agents
/ pharmacology
Occludin
/ metabolism
Recombinant Proteins
/ pharmacology
Vascular Endothelial Growth Factor A
/ genetics
VEGF-A
angiogenesis
angiopoietins
blood–brain barrier
hypoxia
hypoxic brain injury
neurovascular unit
occludin
tight junction proteins
vasculogenesis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 Aug 2022
04 Aug 2022
Historique:
received:
07
07
2022
revised:
29
07
2022
accepted:
30
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Experimental in vivo data have recently shown complementary neuroprotective actions of rhEPO and growth hormone (rhGH) in a neonatal murine model of hypoxic brain injury. Here, we hypothesized that rhGH and rhEPO mediate stabilization of the blood−brain barrier (BBB) and regenerative vascular effects in hypoxic injury to the developing brain. Using an established model of neonatal hypoxia, neonatal mice (P7) were treated i.p. with rhGH (4000 µg/kg) or rhEPO (5000 IU/kg) 0/12/24 h after hypoxic exposure. After a regeneration period of 48 h or 7 d, cerebral mRNA expression of Vegf-A, its receptors and co-receptors, and selected tight junction proteins were determined using qRT-PCR and ELISA. Vessel structures were assessed by Pecam-1 and occludin (Ocln) IHC. While Vegf-A expression increased significantly with rhGH treatment (p < 0.01), expression of the Vegfr and TEK receptor tyrosine kinase (Tie-2) system remained unchanged. RhEPO increased Vegf-A (p < 0.05) and Angpt-2 (p < 0.05) expression. While hypoxia reduced the mean vessel area in the parietal cortex compared to controls (p < 0.05), rhGH and rhEPO prevented this reduction after 48 h of regeneration. Hypoxia significantly reduced the Ocln+ fraction of cortical vascular endothelial cells. Ocln signal intensity increased in the cortex in response to rhGH (p < 0.05) and in the cortex and hippocampus in response to rhEPO (p < 0.05). Our data indicate that rhGH and rhEPO have protective effects on hypoxia-induced BBB disruption and regenerative vascular effects during the post-hypoxic period in the developing brain.
Identifiants
pubmed: 35955834
pii: ijms23158693
doi: 10.3390/ijms23158693
pmc: PMC9368903
pii:
doi:
Substances chimiques
Neuroprotective Agents
0
Occludin
0
Recombinant Proteins
0
Vascular Endothelial Growth Factor A
0
Erythropoietin
11096-26-7
Growth Hormone
9002-72-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Pfizer International
ID : unrestricted reseach grant, Pfizer's Investigator Initiated Research program
Références
Neuroreport. 2019 Mar 6;30(4):262-268
pubmed: 30672890
Gene. 2021 Jan 30;767:145148
pubmed: 32949698
Biomed Res Int. 2021 Aug 19;2021:9988534
pubmed: 34458374
Neuroreport. 2008 Jul 2;19(10):997-1002
pubmed: 18580568
J Biol Chem. 2016 Oct 28;291(44):22913-22923
pubmed: 27601468
Neurobiol Dis. 2016 Nov;95:111-21
pubmed: 27425892
MethodsX. 2015 Nov 07;2:440-5
pubmed: 26740924
Pediatr Res. 2013 Mar;73(3):310-6
pubmed: 23222909
Brain Res. 2018 Jun 1;1688:91-102
pubmed: 29548688
Neural Plast. 2016;2016:8928530
pubmed: 27795859
Transl Stroke Res. 2019 Dec;10(6):672-683
pubmed: 30617994
Brain Sci. 2021 Jul 18;11(7):
pubmed: 34356178
Neurosci Lett. 2004 Jan 2;354(1):64-8
pubmed: 14698483
Int J Mol Sci. 2017 Nov 07;18(11):
pubmed: 29112164
Int J Neurosci. 2015;125(9):693-702
pubmed: 25226558
Pediatr Res. 2007 Jun;61(6):671-5
pubmed: 17426655
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Stroke. 2018 May;49(5):1257-1266
pubmed: 29636425
Transl Pediatr. 2022 Jan;11(1):20-32
pubmed: 35242649
J Physiol. 2018 Dec;596(23):6043-6062
pubmed: 29873394
Children (Basel). 2021 Nov 22;8(11):
pubmed: 34828791
Dev Neurosci. 2017;39(1-4):298-309
pubmed: 28346912
Neuroscience. 2011 Nov 24;196:237-50
pubmed: 21888951
Bioengineered. 2022 Jan;13(1):560-572
pubmed: 34951343
Front Cell Neurosci. 2018 Sep 04;12:288
pubmed: 30233326
Front Cell Neurosci. 2018 Nov 27;12:458
pubmed: 30542269
Int J Mol Sci. 2020 Dec 28;22(1):
pubmed: 33379239
Neurobiol Dis. 2021 Jan;148:105200
pubmed: 33248237
Front Neurol. 2017 Jun 12;8:244
pubmed: 28659854
Brain Res Brain Res Rev. 1995 Nov;21(3):246-84
pubmed: 8806016
Front Neurosci. 2020 Mar 20;14:244
pubmed: 32265643
Int J Mol Sci. 2020 Jan 17;21(2):
pubmed: 31963456
Acta Neuropathol. 2016 May;131(5):753-73
pubmed: 26932603
Endocrinology. 2003 Mar;144(3):1086-97
pubmed: 12586785
J Mol Neurosci. 2013 Feb;49(2):369-79
pubmed: 23001813
Oncotarget. 2017 Sep 8;8(43):75308-75325
pubmed: 29088867
Exp Brain Res. 2006 Aug;173(2):267-73
pubmed: 16633806
Brain Res. 2011 Apr 12;1384:140-50
pubmed: 21295557
Arch Pharm Res. 2020 May;43(5):514-525
pubmed: 32436127
Neuroreport. 2019 Aug 7;30(11):783-789
pubmed: 31261238
J Mol Neurosci. 2011 Jun;44(2):130-9
pubmed: 21318404
J Neurosurg. 2011 Sep;115(3):550-60
pubmed: 21495821
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Cereb Blood Flow Metab. 2014 Apr;34(4):668-76
pubmed: 24398931
Int J Mol Sci. 2021 Nov 05;22(21):
pubmed: 34769434
J Biol Chem. 2009 Jul 31;284(31):21036-46
pubmed: 19478092
Brain Inj. 2016;30(4):462-7
pubmed: 26934476
Neonatology. 2014;106(2):143-8
pubmed: 24969821
Growth Horm IGF Res. 2020 Feb;50:42-47
pubmed: 31862540
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4532-4547
pubmed: 31675424
Exp Eye Res. 2018 Jan;166:1-12
pubmed: 29030174
J Mol Cell Cardiol. 2007 Feb;42(2):390-9
pubmed: 17174322
Neural Plast. 2021 Sep 16;2021:9990166
pubmed: 34567109
Metab Brain Dis. 2016 Aug;31(4):827-35
pubmed: 26943480
Int J Mol Sci. 2020 Dec 29;22(1):
pubmed: 33383827
Front Immunol. 2021 Dec 13;12:801985
pubmed: 34966392
Crit Rev Immunol. 2001;21(5):427-49
pubmed: 11942558
Am J Physiol Regul Integr Comp Physiol. 2017 Apr 1;312(4):R539-R548
pubmed: 28228417
Chin Med J (Engl). 2008 Feb 20;121(4):347-54
pubmed: 18304469
Int J Mol Sci. 2017 Jun 24;18(7):
pubmed: 28672801
Pediatr Res. 2007 Apr;61(4):451-5
pubmed: 17515870
J Alzheimers Dis Parkinsonism. 2013 Oct 28;3(4):1000127
pubmed: 24563821
Chin Med J (Engl). 2017 Apr 5;130(7):854-858
pubmed: 28345550
Neuroscience. 2016 Jun 14;325:89-99
pubmed: 27038749
Neurobiol Dis. 2016 Sep;93:57-63
pubmed: 27142685
Stroke. 2007 Oct;38(10):2795-803
pubmed: 17702962
Front Neurosci. 2020 Apr 02;14:280
pubmed: 32300291
Brain Res. 2014 Jun 20;1569:41-7
pubmed: 24796880
BMC Neurosci. 2014 Aug 26;15:100
pubmed: 25156632
Brain Circ. 2020 Sep 30;6(3):152-162
pubmed: 33210038
Endocrinology. 2021 Mar 1;162(3):
pubmed: 33545716
J Cereb Blood Flow Metab. 2008 Jul;28(7):1361-8
pubmed: 18414495
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
3 Biotech. 2019 Apr;9(4):131
pubmed: 30863710
Neuropsychiatr Dis Treat. 2020 Feb 07;16:397-406
pubmed: 32103959
Brain Res. 2016 Nov 15;1651:104-113
pubmed: 27659964
Dev Neurosci. 2019 Mar 5;:1-10
pubmed: 30836371
Neurochem Int. 2019 Jul;127:137-147
pubmed: 30639264